Galapagos Profile



Odds of Distress

Fiscal Quarter End: December 31, 2019
Equity ratings for Galapagos NV are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting August 23, 2019 and ending today November 21, 2019. Click here to learn more.

Galapagos Profile

Next fiscal quarter end is expected on December 31, 2019. Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 918 people. more
Galapagos Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Galapagos NV SEC Filings
Galapagos SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGalapagos NV
CEOOnno StolpeView All
Thematic Classification
Currently Active Investing Idea
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
Business AddressGeneraal De Wittelaan L11 A3
Foreign Associate  Austria
ExchangeBATS Exchange
Phone32 1 534 29 00
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestOctober 31, 2019
Galapagos NV (GLPG) is traded on BATS Exchange in USA. It is located in Generaal De Wittelaan L11 A3 and employs 918 people. Galapagos is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 11.04 B. Galapagos NV conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 61.95 M outstanding shares of which 980.51 K shares are currently shorted by private and institutional investors with about 6.86 trading days to cover. N/A currently holds about 1.57 B in cash with (181.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 28.83.
Check Galapagos Probability Of Bankruptcy

Ownership Allocation (%)

Galapagos Target Price Odds Analysis

Odds Below 187.26HorizonTargetOdds Above 187.26
94.32%30 days 187.26 5.63%
Based on normal probability distribution, the odds of Galapagos to move above current price in 30 days from now is about 5.63 (This Galapagos NV probability density function shows the probability of Galapagos Stock to fall within a particular range of prices over 30 days) .

Galapagos NV Top Holders

Galapagos Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Sands Capital Management LlcCommon Shares2.8 M420.5 M
Federated Investors IncCommon Shares1.6 M241 M
Susquehanna International Group LlpPut Options123.1 K18.8 M
View Galapagos Diagnostics

Galapagos NV Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Galapagos Key Fundamentals

Galapagos Against Markets

Did you try this?

Run Market Hitters Now


Market Hitters

Find equities that experience drastic asymmetry in trading patters, price, volume, or investment outlook.
All  Next Launch Module

Galapagos Upcoming and Recent Events

Galapagos Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportApril 3, 2020
Next Earnings ReportApril 24, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndApril 3, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Galapagos Corporate Filings

Galapagos SEC Reporting

Unclassified Corporate Event

Galapagos Corporate Directors

Katrine Bosley Independent Non-Executive Director
Howard Rowe Non-Executive Independent Director
Harrold Barlingen Non-Executive Director
Please also check Risk vs Return Analysis. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.